OTCMKTS:PVCT Provectus Biopharmaceuticals (PVCT) Stock Price, News & Analysis $0.04 0.00 (-1.65%) As of 10:46 AM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartNews and TrendsSEC Filings About Provectus Biopharmaceuticals Stock (OTCMKTS:PVCT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get PVCT alerts:Sign Up Key Stats Today's Range$0.04▼$0.0450-Day Range$0.04▼$0.0652-Week Range$0.04▼$0.08Volume10,056 shsAverage Volume208,627 shsMarket Capitalization$17.57 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing investigational therapies for cancer and immune-mediated diseases. The company’s research is based primarily on rose bengal, a small-molecule compound that it has formulated for potential use in oncology and dermatology. Provectus’s lead product candidate is PV-10, an intralesional formulation of rose bengal being investigated for the treatment of solid tumors, including melanoma and certain liver cancers. The company has also studied PV-10 in combination with other cancer treatments, with the goal of stimulating localized and systemic immune responses against tumors. PV-10 is investigational and has not been established as an approved commercial therapy. The company has additionally developed PH-10, a topical rose bengal formulation investigated for immune-mediated dermatological conditions such as psoriasis and atopic dermatitis. Provectus Biopharmaceuticals is based in Knoxville, Tennessee, and has historically focused on advancing its rose bengal-based platform through clinical development and strategic collaborations. Information about its current operating activities and leadership may be limited because the company is publicly traded over the counter.AI Generated. May Contain Errors. Read More Receive PVCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Provectus Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PVCT Stock News HeadlinesVisiRose Selected to Present RB-PDAT at ESCRS iNovation® Day 2026 Emerging Company ShowcaseJuly 22, 2026 | globenewswire.comIndependent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same DoseJuly 7, 2026 | globenewswire.comTrump, Schiff and Dalio all point to the same warning signIn 1929, the Dow fell 89 percent and took 25 years to recover. A 60-year-old who held on wasn't made whole until age 85. Today, the national debt sits at 38.86 trillion dollars, a level the market has never faced before. Economists including Peter Schiff and Ray Dalio point to a classic bubble forming.November 13 at 1:00 AM | USA Capital Gold (Ad)Provectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular InfectionsJune 30, 2026 | globenewswire.comProvectus Biopharmaceuticals Launches Veripure™, an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)June 25, 2026 | globenewswire.comProvectus Shareholders Approve Reverse Stock Split AuthorityJune 22, 2026 | tipranks.comProvectus Biopharmaceuticals, Inc. (PVCT) Shareholder/Analyst Call TranscriptJune 18, 2026 | seekingalpha.comProvectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of StockholdersJune 8, 2026 | globenewswire.comSee More Headlines PVCT Stock Analysis - Frequently Asked Questions How have PVCT shares performed this year? Provectus Biopharmaceuticals' stock was trading at $0.0550 on January 1st, 2026. Since then, PVCT stock has decreased by 24.0% and is now trading at $0.0418. How do I buy shares of Provectus Biopharmaceuticals? Shares of PVCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Provectus Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Provectus Biopharmaceuticals investors own include Cisco Systems (CSCO), Intel (INTC), Palantir Technologies (PLTR), Plug Power (PLUG), Tonix Pharmaceuticals (TNXP), Exela Technologies (XELA) and Amprius Technologies (AMPX). Company Calendar Today11/13/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:PVCT Previous SymbolNYSEMKT:PVCT CIK315545 Webwww.provectusbio.com Phone(866) 594-5999Fax866-998-0005Employees6Year Founded2002Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.43 million Net MarginsN/A Pretax Margin-9,731.04% Return on EquityN/A Return on Assets-585.02% Debt Debt-to-Equity RatioN/A Current Ratio0.05 Quick Ratio0.18 Sales & Book Value Annual Sales$340 thousand Price / Sales51.67 Cash FlowN/A Price / Cash FlowN/A Book Value($0.02) per share Price / Book-2.09Miscellaneous Outstanding Shares420,280,000Free Float335,383,000Market Cap$17.57 million OptionableNot Optionable Beta1.04 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (OTCMKTS:PVCT) was last updated on 11/13/2026 by MarketBeat.com Staff. From Our PartnersWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredTrump’s EO to send this $5 stock ripping higher…?President Trump's December executive order declared space a national security and economic priority, fueling a...Traders Agency | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredTrump compared today's market to 1929President Trump warned of a 1929-style depression if Democrats won control of Congress. On November 3, they di...USA Capital Gold | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredURGENT: If you own a home, please review the map below.More than 1,300 red dots are scattered across the country, and 2,800 more are already on the way. Jim Rickards...Paradigm Press | SponsoredUranium Mine Flood That Sparked a 2006 Price Surge ReturnsIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Provectus Biopharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Provectus Biopharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PVCT Stock Alerts